OCEA: Utang jangka cendhak perusahaan Ocean Biomedical, Inc.

Ocean Biomedical, Inc. (OCEA) is developing a diversified portfolio of malaria and tumor medications, mitigating overall risk through project variety. The business model relies on external financing, as the testing phase does not generate regular profits. Its reputation as a scientific development incubator secures venture support, which currently stands at 0.00. Serving as a valuation tool, this chart of short-term liability costs confirms these fundamental indicators.

This metric aggregates daily payments on credit obligations with maturities of up to one year, allowing for an assessment of current liquidity and short-term default risk. The reduction in short-term liabilities for Ocean Biomedical, Inc. (OCEA) confirms financial stabilization, while a low debt load combined with an R&D licensing model minimizes operating expenses, securing growth potential for future margins and free cash flow.